MAP2K7 and colorectal carcinoma: Thus, targeting both MEK (binimetinib) and c-MET (crizotinib) was evaluated in CRC patients with RAS mutant or RAS WT and aberrant c-MET in a completed Phase I clinical trial (NCT02510001), however; final results from this trial are awaited.